iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc., an AI-driven biotech company focused on cardiometabolic and cardiopulmonary diseases, released its Q3 fiscal year 2026 financial results and highlighted key corporate updates. The company secured regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) and Human Research Ethics Committee (HREC) to initiate a Phase 1 clinical trial for IBIO-600, a long-acting anti-myostatin monoclonal antibody designed to preserve lean mass and improve body composition in overweight and obese adults. The randomized, double-blind, placebo-controlled study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics, with the first participant dosing expected in the second quarter of 2026. iBio also presented new preclinical data from an obese non-human primate (NHP) study evaluating IBIO-610, demonstrating a 6.7% reduction in visceral fat and a 5.2% reduction in total fat mass. These findings support the potential of IBIO-610 as a targeted obesity therapy. Additionally, the company expanded its pipeline by developing a selective bispecific antibody aimed at blocking Activin A, GDF8 (myostatin), and GDF11 to address pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This condition represents a significant unmet medical need, and iBio’s approach seeks to reduce cardiac fibrosis and reverse pulmonary vascular remodeling while mitigating risks linked to broader TGFβ ligand blockade. The company’s CEO, Martin Brenner, emphasized the progress across its pipeline, highlighting the potential of IBIO-600 due to its ability to preserve lean mass and improve body composition. Brenner also noted the strategic expansion into PH-HFpEF as a high-priority area for addressing patient needs. These milestones reflect iBio’s commitment to developing differentiated therapies for cardiometabolic and cardiopulmonary diseases. iBio operates as a NASDAQ-listed company with a focus on AI-driven drug discovery and development. The recent regulatory clearance and preclinical data underscore the company’s progress in advancing its therapeutic candidates toward clinical and commercial potential.